ArticleFrontiers in oncology2025

Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer.

Haoqi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.